Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model

Drug Metabolism and Disposition(2022)10.1124/dmd.121.000733Source: DataRank Database

Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model is a research paper published in Drug Metabolism and Disposition (2022). On theSindex it has a DataRank of 0. It has been cited 11 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access11 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 1.94)OA: hybridTopics (48)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Mayur K. Ladumor ORCID,Jashvant D. Unadkat ORCID,Jinfu Peng

Live enrichment

PubMed:35149540 PMC:PMC9073947 OpenAlex:https://openalex.org/W4210976994

NIDA NIH HHS

Grant: P01 DA032507

National Institutes of Health

Grant: 5P01DA032507-07

Pharmacology of Drugs of Abuse During Pregnancy

FWCI

1.94

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

2025

2026

hybridLicense: cc-by

journalhttps://dmd.aspetjournals.org/content/dmd/50/5/613.full.pdf

publisherhttps://dmd.aspetjournals.org/content/dmd/50/5/613.full.pdf

publisherhttps://api.elsevier.com/content/article/PII:S0090955624007906?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0090955624007906?httpAccept=text/plain

publisherhttps://syndication.highwire.org/content/doi/10.1124/dmd.121.000733

Fields of Study

Pregnancy and Medication ImpactPregnancy and preeclampsia studiesHIV/AIDS drug development and treatment03 medical and health sciences0302 clinical medicine

MeSH Terms

Imatinib MesylateATP Binding Cassette Transporter, Subfamily G, Member 2Breast NeoplasmsFemaleFetusHumansModels, BiologicalNeoplasm ProteinsPlacentaPregnancyATP Binding Cassette Transporter, Subfamily BNelfinavirATP Binding Cassette Transporter, Subfamily B, Member 1

Keywords

PharmacokineticsBreast cancerSteady state (chemistry)P-glycoproteinSubstrate (aquarium)ChemistryFetusGlycoproteinPharmacologyInternal medicineEndocrinologyBiologyCancerMedicineMultiple drug resistancePregnancyBiochemistryGeneticsATP Binding Cassette Transporter, Subfamily BNelfinavirPlacentaBreast NeoplasmsArticlesModels, BiologicalNeoplasm ProteinsImatinib MesylateATP Binding Cassette Transporter, Subfamily G, Member 2HumansFemaleATP Binding Cassette Transporter, Subfamily B, Member 1

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being